Fiscal Year 2017 Kidney Cancer Research Program Reference Table of Award Mechanisms and Submission Requirements

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
Consortium Development Award Go to: • Program Announcement • General Application Instructions Grants.gov Funding Opportunity Number: W81XWH-17-KCRP-CDA	An eligible Principal Investigator (who will be the Consortium Director) will be a faculty member at or above Assistant Professor (or equivalent) level. co-PIs should be at or above Assistant Professor (or equivalent) level.	gator (who will be the rtium Director) will be try member at or above ant Professor (or lent) level. should be at or above ant Professor (or lent) Provides support to create a Coordinating Center and to lent lent lent lent lent lent lent lent	Pre-Application (Letter of Intent): December 20, 2017 5:00 p.m. Eastern time (ET) Application: January 4, 2018 11:59 p.m. ET	
		 Minimum of three separate institutes: one Coordinating Center and at least two Clinical Sites (other than the Coordinating Center) Awardee will be eligible to 		
		apply for FY19 Consortium Award, if funds are available		

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
Idea Development Award Go to: Program Announcement General Application Instructions Grants.gov Funding Opportunity Number: W81XWH-17-KCRP-IDA	Established Investigators: Independent investigators at or above the level of Assistant Professor (or equivalent) and 10 years or more from a terminal degree; or Early Career Investigators: Investigators at the level of Assistant Professor, Instructor, or Assistant Research Professor (or equivalent) and less than 10 years from a terminal degree (excluding time spent in medical residency or family medical leave) at the time of application submission deadline are eligible	 Supports new ideas that represent innovative, highrisk/high-gain approaches to kidney cancer research, and have the potential to make an important contribution to kidney cancer. Preliminary data is required Innovation and Impact are the most important review criteria. Clinical Trials are not allowed Areas of Emphasis include: Microenvironment, Metabolism, Chromatin and Gene Regulation, Rare Cancers, Screening, Early Detection, Novel Imaging Technologies, Liquid Biopsy, Biomarker Development, Prognosis, Targeted Therapies, Immunotherapies, Resistance, Novel Interventions, Surgical, Ablation, Radiation, Prognosis, Managing Toxicity, Survivorship and Patient Experience, Surveillance, Genetic Risk Factors. 	 Maximum funding of \$400,000 in direct costs (plus indirect costs) Period of performance not to exceed 3 years Indirect costs may be proposed in accordance with the institution's negotiated rate agreement. 	Pre-Application (Letter of Intent): December 20, 2017 5:00 p.m. Eastern time (ET) Application: January 4, 2018 11:59 p.m. ET

Award Mechanism	Eligibility	Key Mechanism Elements	Funding	Submission Deadline
Concept Award Go to: • Program Announcement • General Application Instructions Grants.gov Funding Opportunity Number: W81XWH-17-KCRP-CA	All investigators at or above the level of postdoctoral fellow (or equivalent) are eligible.	 Supports highly innovative, untested, potentially groundbreaking concepts in kidney cancer Emphasis on innovation Clinical trials are not allowed Preliminary data not allowed Blinded review 	 Maximum funding of \$75,000 for direct costs (plus indirect costs) Maximum period of performance is 1 year Indirect costs may be proposed in accordance with the institution's negotiated rate agreement. 	Pre-Application (Letter of Intent): December 20, 2017 5:00 p.m. Eastern time (ET) Application: January 4, 2018 11:59 p.m. ET
Translational Research Partnership Award Go to: • Program Announcement • General Application Instructions Grants.gov Funding Opportunity Number: W81XWH-17-KCRP-TRPA	The Initiating PI must be at or above the level of Assistant Professor or equivalent. The Partnering PI must be at or above the level of Assistant Professor or equivalent. Postdoctoral fellows are not eligible to be Partnering PIs	 Supports partnerships between clinicians and laboratory scientists that accelerate ideas in kidney cancer into clinical applications Supports translational correlative studies Preliminary data required Clinical trials are not allowed 	 Maximum funding of \$600,000 for direct costs (plus indirect costs) Maximum period of performance is 3 years Indirect costs may be proposed in accordance with the institution's negotiated rate agreement. 	Pre-Application (Letter of Intent): December 20, 2017 5:00 p.m. Eastern time (ET) Application: January 4, 2018 11:59 p.m. ET